ProCE Banner Activity

CE / CME

Psoriasis/Psoriatic Arthritis Update: A Team Based Approach to Elevated Care

Multimedia
In this interactive on-demand Webcast, expert faculty discuss best practices and emerging strategies in the holistic management of patients with psoriasis and PsA.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: August 27, 2021

Expiration: August 26, 2022

No longer available for credit.

Share

Faculty

April W. Armstrong

April W. Armstrong, MD, MPH

Professor of Dermatology and Associate Dean
Department of Dermatology
Keck School of Medicine of USC
Associate Dean for Clinical Research
Department of Dermatology
Director
Clinical Research Support, Southern California Clinical and Translational Science Institute (SC CTSI)
Vice Chair
Director,
Clinical Trials and Outcomes Research
Director, Psoriasis Program
Los Angeles, California

Philip Mease

Philip Mease, MD, MACR

Director, Rheumatology Research
Providence Swedish Medical Center
Clinical Professor
University of Washington School of Medicine
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Janssen administered by Scientific Affairs

Target Audience

This program is intended for rheumatologists, dermatologists, primary care physicians, nurse practitioners, and other healthcare professionals who care for patients with psoriatic disease.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply guideline recommendations for psoriasis and PsA treatment selection according to disease severity, treatment history, and functional and QoL status
  • Describe common comorbidities associated with psoriatic disease and strategies for identifying and managing these conditions
  • Outline coordination of care with other healthcare professionals that fosters a whole-patient approach to psoriatic disease and related conditions and concerns

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

April W. Armstrong, MD, MPH

Professor of Dermatology and Associate Dean
Department of Dermatology
Keck School of Medicine of USC
Associate Dean for Clinical Research
Department of Dermatology
Director
Clinical Research Support, Southern California Clinical and Translational Science Institute (SC CTSI)
Vice Chair
Director,
Clinical Trials and Outcomes Research
Director, Psoriasis Program
Los Angeles, California

April W. Armstrong, MD, MPH, has disclosed that she has received consulting fees from AbbVie, Aslan, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavent, Dermira, EPI Health, Incyte, Janssen, Leo, Lilly, Novartis, Ortho, Parexel, Pfizer, Regeneron, Sanofi, Sun, and UCB and funds for research support from Bristol-Myers Squibb, Dermavent, Dermira, Lilly, Leo, Pfizer, and UCB.

Philip Mease, MD, MACR

Director, Rheumatology Research
Providence Swedish Medical Center
Clinical Professor
University of Washington School of Medicine
Seattle, Washington

Philip Mease, MD, MACR, has disclosed that he has received consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; funds for research from AbbVie, Amgen, Bristol-Myers Squibb, Galapagos, Gilead Sciences, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and fees for non-CME/CE services from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB.

Staff Disclosure

Staff

Craig Borders,

Vice President, Managing Scientific Director

Craig Borders has no relevant conflicts of interest to report.

Ruth Cohen,

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Jennifer Simpson, DNP

Jennifer Simpson, DNP, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 27, 2021, through August 26, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve learners’ knowledge and competence in applying current and emerging treatment strategies in the holistic management of patients with psoriasis and PsA.